Myelodysplastic Syndromes
The new indication is for use of the alkylating agent with fludarabine in a preparatory combination for allogeneic HSCT.
Juan Jose Rodriguez-Sevilla, MD, PhD, summarizes current clinical knowledge about inflammation within MDS pathobiology.
An MDS HSPC signature generated from the model presents possible targets for treatment in patients with low-risk disease.
The study's results especially highlight potential aberrant gene regulation by ZMAT2 and SMARCD3.
The study showed a mortality risk reduction benefit in certain mutations while for others larger studies are needed.
Researchers noted that confirmation of this relationship in lower-risk disease would require a larger study.
Researchers argue from their findings that the 2023 criteria more accurately present the performance of ivosidenib in MDS.
The combination in a phase II trial produced high complete response rates in patients with newly diagnosed AML.
Researchers also analyzed baseline stem cells for insight into patient response versus non-response to the combination.
The combination was compared with decitabine monotherapy in a multicenter, open-label, RCT.
A study evaluated azacitidine combined with ipilimumab or nivolumab and triplet of these agents in treatment-naive MDS.
Across several patient subgroups luspatercept was observed to produce longer durations of transfusion independence.
Advertisement
Expert Interviews on Hematology
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.